Navigation Links
Jekyll and Hyde: Cells' executioner can also stave off death
Date:3/3/2011

ATLANTA -- An enzyme viewed as an executioner, because it can push cells to commit suicide, may actually short circuit a second form of cell death, researchers at Emory University School of Medicine have discovered.

The finding could shift drug discovery efforts, by leading scientists to rethink how proposed anti-cancer and anti-inflammatory drugs that target the enzyme, called caspase 8, are supposed to work. The results are described in this week's Nature.

Caspase 8 has been described as "the killer you can't live without." This enzyme plays a key role in apoptosis, a form of cellular suicide important for the development of all multicellular organisms, and in defense against viral infections. Mice lacking caspase 8 die before birth, because their blood vessels and blood-forming stem cells fail to develop properly. In the Nature paper, Emory researchers show that mice without caspase 8 develop normally if they also lack another enzyme called RIP3.

"The surprising aspect is that caspase 8 appears to have two functions: one that initiates apoptosis and a second that restrains an independent programmed death pathway," says senior author Ed Mocarski, PhD, Robert W. Woodruff Professor of Microbiology and Immunology at Emory Vaccine Center and Emory University School of Medicine.

Graduate student William Kaiser, in Emory's Microbiology and Molecular Genetics program, is the first author of the paper. Other Emory authors include Tamara Caspary, PhD, assistant professor of human genetics, as well as students and postdoctoral fellows from both Emory labs.

"It's remarkable to be able to rescue mice from embryonic death," Caspary says. "I was surprised that the mice are even born, since these enzymes are basic parts of the cellular machinery."

In humans, a lack of caspase 8 has been linked to immune disorders and skin diseases such as eczema, while too much caspase 8 activity has been connected with diabetes.
'/>"/>

Contact: Joe Quimby
joseph.quimby@emory.edu
404-727-3366
Emory University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Discovery of the Jekyll-and-Hyde factors in coral bleaching
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. NSF funds new Center for the Physics of Living Cells at Illinois
4. When cells go bad
5. The role of stem cells in renewing the cornea
6. Breast cancer cells recycle to escape death by hormonal therapy
7. Models of eel cells suggest electrifying possibilities
8. Scientists identify a molecule that coordinates the movement of cells
9. Form of Crohns disease traced to disabled gut cells
10. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
11. Researchers design artificial cells that could power medical implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... in Antarctica, funded by the National Science Foundation (NSF), have ... and greenhouse gases in the atmosphere that extends back 68,000 ... the ice containing the record is known as the WAIS ... the core contain uniquely detailed information on past environmental conditions ...
... molds and fungi, bacteria and viruses. To kill them off ... are, as a rule, treated chemically. However, recently this method ... have been withdrawn, but the granting of new permits has ... E. coli infection which was caused by beansprout ...
... ARBORMany medically minded researchers are in hot pursuit of ... and the interiors of cells, but University of Michigan ... to overcome: escaping the bloodstream. Drug delivery ... medicines could be more effective at lower doses and ...
Cached Biology News:Antarctic ice core contains unrivaled detail of past climate 2Antarctic ice core contains unrivaled detail of past climate 3Healthy seeds -- treated environmentally friendly 2Healthy seeds -- treated environmentally friendly 3Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 2Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 3
(Date:12/13/2014)... 2014 The “Global Synthetic Biology ... drivers, threats, opportunities, and challenges. , The global ... players, namely, Thermo Fisher Scientific, Inc. (U.S.), DuPont ... jointly accounted for approximately ~65% of the total ... Copy for This Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html ...
(Date:12/13/2014)... York (PRWEB) December 13, 2014 QuickSTAT ... global network and Cold Chain capabilities, and is delighted ... in Paris, France, to serve Life Science clients in ... equipped with a controlled-ambient warehouse, will provide 24/7 transportation ... vaccines and investigational drugs, patient-clinical specimens, API, following IATA ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Glucose Sensors: the Next Generation" ... http://photos.prnewswire.com/prnh/20130307/600769 The convergence of ... giving hope for a better future to millions ... can measure glucose levels accurately and reliably have ...
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced that ... the company has regained compliance with Marketplace Rule,4450(a)(5) (the ... bid,price of the Company,s common stock. Nasdaq had previously ... stock had failed to maintain a,minimum bid price of ...
... 29 /Xinhua-PRNewswire-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" ... Republic of China ("PRC"),today reported solid financial results for ... Fourth Quarter Fiscal 2007 Highlights, -- ... the fourth quarter of 2006, ...
... Verizon Keynote at Leading Pharmaceutical Communication Event, Where Executives Gather to ... for Pharmaceutical, Biotech and Medical Technology ... ... pleased to announce the participation of two keynote speakers from the,U.S. Food ...
Cached Biology Technology:Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 2Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 3Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 4Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 5Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 6Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 7Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 8Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 9FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 2FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 3
Proteinase K Buffer 3.9 ml...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Glutathione Agarose Beads 10 ml...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Biology Products: